Hormone therapy of operable breast cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The randomized trials have assessed the effects of 1-2 year or 5 years of adjuvant tamoxifen administration in breast cancer patients. The data for 1433 women with early breast cancer (ER-positive tumours or unknown) were analyzed. For trials of 1-2 years and about 5 years of adjuvant tamoxifen administration, the proportional recurrence reduction during 5-10 years of follow up was 16,1 and 27 % respectively (p<0,05). The corresponding proportional mortality reduction was 14 and 26,6 % respectively (p<0,05) The proportional mortality reduction was similar for patients with node-positive and node-negative breast cancer, but the absolute mortality reduction was greater in node-positive women. The neoadjuvant treatment of breast cancer patients with letrozole was more effective than treatment with tamoxifen (p<0,05).

About the authors

V. F. Semiglazov

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Author for correspondence.
Email: medaj@eco-vector.com

член-корреспондент РАМН

Russian Federation, St. Petersburg

V. V. Semiglazov

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg

V. G. Ivanov

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg

E. K. Zhiltsova

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg

N. U. Barasch

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg

E. V. Tsyrlina

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg

G. A. Daschyan

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg

A. A. Bozhok

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg

K. Sh. Nurgaziyev

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg

E. E. Topuzov

Petrov Research Institute of Oncology of the Ministry of Health of Russian Federation

Email: medaj@eco-vector.com
Russian Federation, St. Petersburg

References

  1. Бассалык Л. С., Пашинцева Л. П. Биохимические методы в диагностике злокачественных онкологов. Л., 1986. С. 147-148.
  2. Бассалык Л. С. (ред.) Рецепторы стероидных гормонов в опухолях человека. М.: Медицина, 1997. 224 с.
  3. Берштейн Л. М. Гормональный канцерогенез. Спб.: Наука, 2000. 199 с.
  4. Возный Э. Гормонотерапия рака молочной железы. М., 1999.
  5. Гарин А. М. Сложные ситуации, трудные и спорные вопросы ведения и лечения больных раком молочной железы // Новое в терапии рака молочной железы / Ред. Н. И. Переводчикова. 1998. С. 67-76.
  6. Гарин А. М. Принципы и возможности современной эндокриннотерапии опухолей. М., 2000. 207 с.
  7. Моисеенко В. М., Семиглазов В. В., Тюляндин С. А. Современное лекарственное лечение местно-распространенного и метастатического рака молочной железы. Спб.: Грифон, 1997. 254 с.
  8. Семиглазов В. Ф., Нургазиев К. Ш., Арзуманов А. С. Опухоли молочной железы (лечение и профилактика). 2001. 346 с.
  9. Семиглазов В. Ф. Сколько лет должны принимать тамоксифен больные раком молочной железы? Международная программа ATLAS ответит на этот вопрос // Вопр. онкологии. 1998. № 4. С. 373-377.
  10. Тюляндин С. А. Значение выключения функции яичников у больных операбельным раком молочной железы с сохраненной менструальной функцией. М., 2001.
  11. Arteaga C., Koli K., Dugger T. et al. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta // J. Natl. Cancer Inst. 1999. Vol. 91. P. 46-53.
  12. Baum M. Use of aromatase inhibitors in the adjuvant treatment of breast cancer // Endocrine-Related Cancer. 1999. Vol. 6. P. 231-234.
  13. Beatson G. T. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases // Lancet. 1896. Vol. 2. P. 104-107.
  14. Bernstein L., Deapen D., Cerhan J. et al. Tamoxifen therapy for breast cancer and endometrial cancer risk // Breast Diseases. 2000. Vol. 11.P.213.
  15. Dowsett M., Tobias J., Howell A. et al. The effect of anastrozole on the pharmacokinetics of tamoxifen in postmenopausal women with early breast cancer // British Journal of Cancer. 1999. Vol. 77. P. 300-308.
  16. Dowsett M., Pfister C., Johnston S. et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer // Breast Diseases. 2000. Vol. 11. P. 212.
  17. Dixon M., Renshaw L., Bellamy D. et al. Arimidex as neoadjuvant therapy causes large reductions in tumour volume in postmenopausal women with large operable breast cancer // Proc. ASCO meeting. Atlanta, 1999. Vol. 345. P. 92a.
  18. Dixon J. M. Neoadjuvant endocrine therapy // Aromatase inhibition and breast cancer / Ed. W. Miller and R. Santen. New York, 2001. P. 103-116.
  19. Dixon J., Love C., Tucker S. et al. Letrozole as primary medical therapy for locally advanced breast cancer // Breast Cancer Res. Treat. 1997. Vol. 46. P. 213.
  20. Cole M. P., Jones C. T. A., Todd I. D. H. A new antiestrogenic agent in last breast cancer: A preliminary appraisal of ICI 46, 474 // Br. J. Cancer. 1971. Vol. 25. P. 270-275.
  21. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overwiew of the randomised trials // Lancet. 1998. Vol. 351. P. 1451-1467.
  22. Eiermann W., Mauriac L., Semiglazov V. et al. Neoadjuvant treatment of postmenopausal breast cancer patients and impact on breast conserving surgery: A double blind randomized study comparing letrozole to tamoxifen. The Letrozole Neoadjuvant Breast Cancer Study Group // Ann. Oncol. 2000. Vol. 11 (suppl. 11). P. 16-17.
  23. Howell A., Defriend D., Robertson et al. Response to specific antiestrogen (ICI 182, 780) in tamoxifen-resistant breast cancer // Lancet. 1995. Vol. 345. P. 29-30.
  24. Ingle J., Suman V., Johnson P. et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women // Breast Diseases. 2000. Vol. 11. P. 210-211.
  25. Jensen E. V., Jacobson H. I. Basic guides to the mechanism of estrogen action // Recent Prog. Norm. Res. 1962. Vol. 18. P. 387-414.
  26. Jensen Е. V., Block G. Е., Smith S. et al. Estrogen receptors and breast cancer response to adrenalectomy // Prediction of response in cancer therapy / Ed. T. C. Hall. Monogr. Natl. Cancer Inst. 1971. Vol. 34. P. 55-70.
  27. Jonat W. Zoladex TM (goserelin) vs CMF as adjuvant therapy in pre-/perimenopausal nodepositive breast cancer: first efficacy results from ZEBRA Study // Eur. J. Cancer. 2000. Vol. 36 (suppl. 5). P. 67 (S. 132).
  28. Jordan V. C. The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur Walpole // Breast Cancer Res. Treat. 1988. Vol. 11. P. 197-209.
  29. Jordan V. C. Origins of antiestrogens // Estrogens and Antiestrogens: Basic and Clinical Aspect / Eds. R. Lindsay, D. W. Dempster, V. C. Jordan. Philadelphia: Lippmcott-Raven, 1997. Vol. 11. P. 9-20.
  30. Lerner L. J., Holthaus F. J., Thompson C. R. A nonsteroidal estrogen antagonist 1-p-2-diethylaminoethoxyphenyl-1 -phenyl-2-p-methoxyphenylethanol // Endocrinol. 1958. Vol. 63. P. 215-318.
  31. Lerner L. J., Jordan V. C. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture // Cancer Res. 1990. Vol. 50. P. 4177-4189.
  32. Lonning P. Exemestane in breast cancer: current status and future directions // Clinical Breast Cancer. 2000. Vol. 1 (suppl.). P. 28-33.
  33. Lykkesfeldt A. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer //Acta Oncol. 1996. Vol. 35. P. 9-14.
  34. Mamounas E. Antiaromatase agents after adjuvant tamoxifen: rationale and clinical implications // Clinical Breast Cancer. 2000. Vol. 1 (suppl.). P. 22-27.
  35. Estrogen Receptors in Human Breast Cancer / Ed. W. L. McGuire, P. P. Carbone, E. P. Vollmer. New York: Raven Press, 1975. 240 p.
  36. Miller W., Dixon M. Antiaromatase agent: preclinical data and neoadjuvant therapy // Clinical Breast Cancer. 2000. Vol. 1 (suppl.). P. 9-14.
  37. Miller W., Santen R. Aromatase inhibition and breast cancer. New York, 2001. 309 p.
  38. Mustacchi G., Milani S., Pluchinotta A. et al. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G. R. E. T. A. Trial Group for Research on Endocrine Therapy in the Elderly // Anticancer Res. 1994. Vol. 14. № 5B. P. 2197-2200.
  39. Paepke S., Apffelstaedt I., Semiglazov V. et al. Neoadjuvant treatment of postmenopausal breast cancer patients with letrozole (FEMARA): a randomized multicenter study versus tamoxifen // Proc. EBCC-II-Brussels. 2000. P. 179.
  40. Robertson J. F., Ellis I. O., Elston C. W. et al. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up // Eur. J. Cancer. 1992. Vol. 28. P. 908-910.
  41. Santen R., Yue W., Naftolin F. et al. The potential of aromatase inhibitors in breast cancer prevention // Endocr. Relat. Cancer. 1999. Vol. 6. P. 235-243.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2002 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.